Your Article Summary
See Latest ArticlesDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
Cancer, 06/23/09
Kantarjian H et al. - In a trial to assess the use of dasatinib and high-dose imatinib in chronic-phase chronic myeloid leukemia (CP-CML) resistant to imatinib, it was reported that after 2 yrs of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival (PFS) rates relative to high-dose imatinib.
Methods- A phase 2, open-label study was initiated of 150 pts with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n=101) or high-dose imatinib 800 mg (400 mg twice daily; n=49).
- At a minimum follow-up of 2 yrs, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%), major cytogenetic response (MCyR) (53% vs 33%), and complete cytogenetic response (44% vs 18%).
- At 18 mos, MCyR was maintained in 90% of pts on the dasatinib arm and in 74% of pts on the high-dose imatinib arm.
- Major molecular response rates were more frequent with dasatinib than with high-dose imatinib (29% vs 12%).
- Estimated PFS also favored dasatinib.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Telavancin: A Novel Lipoglycopeptide
Clinical Infectious Diseases, 11/16/09
Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Importance of Purulence in Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections
Journal of the American Board of Family Medicine, 11/09/09
VanA-Type Vancomycin-Resistant Staphylococcus aureus
Antimicrobial Agents and Chemotherapy, 11/05/09
Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09